Kyselina tauroursodeoxycholová (TUDCA)

Literatúra

  1. Lepercq P, et al. Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria. Br J Nutr. (2005)
  2. Amaral JD, et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. (2009)
  3. Invernizzi P, et al. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology. (1999)
  4. Setchell KD, et al. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut. (1996)
  5. Zouboulis-Vafiadis I, Dumont M, Erlinger S. Conjugation is rate limiting in hepatic transport of ursodeoxycholate in the rat. Am J Physiol. (1982)
  6. Keene CD, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington’s disease. Exp Neurol. (2001)
  7. Bernales S, Papa FR, Walter P. Intracellular signaling by the unfolded protein response. Annu Rev Cell Dev Biol. (2006)
  8. Ozcan U, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. (2006)
  9. Ben Mosbah I, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis. (2010)
  10. Gao X, et al. The nephroprotective effect of tauroursodeoxycholic Acid on ischaemia/reperfusion-induced acute kidney injury by inhibiting endoplasmic reticulum stress. Basic Clin Pharmacol Toxicol. (2012)
  11. Hertl M, et al. In vivo protection of the pig liver against ischemia/reperfusion injury by tauroursodeoxycholate. Langenbecks Arch Surg. (1999)
  12. Anderson CD, et al. Endoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allografts. Liver Transpl. (2011)
  13. Rodrigues CM, et al. Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab. (2002)
  14. Amin A, et al. Chronic inhibition of endoplasmic reticulum stress and inflammation prevents ischaemia-induced vascular pathology in type II diabetic mice. J Pathol. (2012)
  15. Achard CS, Laybutt DR. Lipid-induced endoplasmic reticulum stress in liver cells results in two distinct outcomes: adaptation with enhanced insulin signaling or insulin resistance. Endocrinology. (2012)
  16. Falasca L, et al. Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver: a pilot study in transplant recipients. Transplantation. (2001)
  17. Marzioni M, et al. Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol. (2006)
  18. Henkel AS, et al. Reducing endoplasmic reticulum stress does not improve steatohepatitis in mice fed a methionine- and choline-deficient diet. Am J Physiol Gastrointest Liver Physiol. (2012)
  19. Panella C, et al. Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease. Ital J Gastroenterol. (1995)
  20. Solá S, et al. Membrane structural changes support the involvement of mitochondria in the bile salt-induced apoptosis of rat hepatocytes. Clin Sci (Lond). (2002)
  21. Schölmerich J, et al. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties–studies on isolated hepatocytes and lipid membrane vesicles. Hepatology. (1984)
  22. Oelberg DG, Lester R. Cellular mechanisms of cholestasis. Annu Rev Med. (1986)
  23. Attili AF, et al. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses. (1986)
  24. Yousef IM, et al. Liver cell membrane solubilization may control maximum secretory rate of cholic acid in the rat. Am J Physiol. (1987)
  25. Piazza F, et al. Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates‘ protection of liver damage induced by chenodeoxycholic acid. Dig Liver Dis. (2000)
  26. Salen G, Tint GS, Shefer S. Treatment of cholesterol gallstones with litholytic bile acids. Gastroenterol Clin North Am. (1991)
  27. Cetta F, Montalto G, Pacchiarotti MC. Gallstone opacification during cholelitholytic treatment. Am J Gastroenterol. (1997)
  28. Diehl AK. Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am. (1991)
  29. Attili AF, et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology. (1997)
  30. Therapy of gallstone disease: What it was, what it is, what it will be.
  31. Lanzini A, Northfield TC. Pharmacological treatment of gallstones. Practical guidelines. Drugs. (1994)
  32. Portincasa P, et al. Medicinal treatments of cholesterol gallstones: old, current and new perspectives. Curr Med Chem. (2009)
  33. Diseases of the Liver and Biliary System, Eleventh Edition.
  34. Lanzini A, Facchinetti D, Northfield TC. Maintenance of hepatic bile acid secretion rate during overnight fasting by bedtime bile acid administration. Gastroenterology. (1988)
  35. Kupfer RM, Maudgal DP, Northfield TC. Gallstone dissolution rate during chenic acid therapy. Effect of bedtime administration plus low cholesterol diet. Dig Dis Sci. (1982)
  36. Paumgartner G, Pauletzki J, Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol Suppl. (1994)
  37. Bazzoli F, et al. Acquired gallstone opacification during cholelitholytic treatment with chenodeoxyholic, ursodeoxycholic, and tauroursodeoxycholic acids. Am J Gastroenterol. (1995)
  38. Rodrigues CM, et al. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem. (2000)
  39. Keene CD, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc Natl Acad Sci U S A. (2002)
  40. Ved R, et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem. (2005)
  41. Duan WM, et al. Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson’s disease. Cell Transplant. (2002)
  42. Rodrigues CM, et al. Bilirubin and amyloid-beta peptide induce cytochrome c release through mitochondrial membrane permeabilization. Mol Med. (2000)
  43. Ramalho RM, et al. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer’s disease mutant neuroblastoma cells. J Neurochem. (2006)
  44. Ramalho RM, et al. Apoptosis in transgenic mice expressing the P301L mutated form of human tau. Mol Med. (2008)
  45. Ramalho RM, et al. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem. (2004)
  46. Rodrigues CM, et al. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun. (2001)
  47. Rodrigues CM, et al. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A. (2003)
  48. Ozcan U, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. (2004)
  49. Hirosumi J, et al. A central role for JNK in obesity and insulin resistance. Nature. (2002)
  50. Urano F, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. (2000)
  51. Rieusset J, et al. Reduction of endoplasmic reticulum stress using chemical chaperones or Grp78 overexpression does not protect muscle cells from palmitate-induced insulin resistance. Biochem Biophys Res Commun. (2012)
  52. da-Silva WS, et al. The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditure. FEBS Lett. (2011)
  53. Tang C, et al. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress. Diabetologia. (2012)
  54. Boden G, et al. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol. (1996)
  55. Kars M, et al. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. (2010)
  56. Ockenga J, et al. Plasma bile acids are associated with energy expenditure and thyroid function in humans. J Clin Endocrinol Metab. (2012)
  57. Brufau G, et al. Plasma bile acids are not associated with energy metabolism in humans. Nutr Metab (Lond). (2010)
  58. Sagar GD, et al. Ubiquitination-induced conformational change within the deiodinase dimer is a switch regulating enzyme activity. Mol Cell Biol. (2007)
  59. Watanabe M, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. (2006)
  60. Zhou L, et al. DsbA-L alleviates endoplasmic reticulum stress-induced adiponectin downregulation. Diabetes. (2010)
  61. Kim EK, et al. Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth. PLoS One. (2017)
  62. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. (2007)
  63. Krishna-Subramanian S, et al. UDCA slows down intestinal cell proliferation by inducing high and sustained ERK phosphorylation. Int J Cancer. (2012)
  64. Goulet AC, et al. Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis. (2005)
  65. Henzel K, et al. Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid. Biochim Biophys Acta. (2004)
  66. Neuman MG, et al. Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line. Gastroenterology. (1995)
  67. Leuschner U, et al. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Ital J Gastroenterol. (1995)
  68. Angelico M, et al. One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation. Ital J Gastroenterol Hepatol. (1999)
  69. Lindor KD, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. (2009)
  70. Maggs JR, Chapman RW. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol. (2008)
  71. O’Brien CB, et al. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology. (1991)
  72. Beuers U, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. (1992)
  73. Stiehl A, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol. (1994)
  74. Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?. Hepatology. (2009)
  75. Larghi A, et al. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Aliment Pharmacol Ther. (1997)
  76. Crosignani A, et al. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci. (1996)
  77. Crosignani A, et al. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepatogastroenterology. (1998)